Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class ASSE: 603707

"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on Participation in Subscription of Private Fund Units by Wholly-owned Subsidiary

Sep 25, 2026 · Issued by Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange

Filed with SSE · Sep 25, 2026

Announcement on Participation in Subscription of Private Fund Units by Wholly-owned Subsidiary

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Company analysis

Earlier from Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A

"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on Subsidiary's Receipt of U.S. FDA Approval for an Additional Manufacturing Site for Amikacin Sulfate InjectionSep 23
"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on Subsidiary's Receipt of U.S. FDA Approval for an Additional Manufacturing Site for Adalimumab InjectionSep 2
"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on Change in Accounting PoliciesAug 28
"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on the U.S. FDA Approval of the Subsidiary's Insulin Aspart InjectionJul 28

All Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A news releases